Dopamine – 2018

international conference

May 19-20, 2018


Dear Colleagues,

welcome to international conference : ” Dopamine – 2018″ !

It is our great pleasure and privilege to invite you toKiev,Ukraine in May 2018 to take part in the Dopamine-2018 medical conference. The NBScience Society is planning a meeting of outstanding scientific interest and quality in the beautiful place – Kiev,Ukraine.

The scientific programme has been meticulously prepared and organised by the Scientific Committee. As ever, it will allow for major coverage of the main clinical areas of interest , and it will also feature cutting-edge scientific discoveries. There will be an extended CME programme at the day of the opening ceremony, as usual one of the jewels in the crown of NBScience conferences, and within that programme there will be many presentations from the NBScience working groups. As always, the late breaking clinical trial session promises to be exciting and stimulating. The Young Scientists Platform will also be prominent in the conference programme.

Join us for the Dopamine 2018 Meeting!
This is the meeting where scientists develop new technologies to enhance what they see therefore allowing them to do their job better.
Please contact NBScience Education department about customising content to meet your needs.


Access the highest quality of education and the latest advancements:

*Earn CME credit.

*Learn from accomplished faculty across a variety of subspecialties.

*Enhance your skills and performance.

We are all really hoping you will find the Kievwelcoming, the programme exciting, the company stimulating and the experience enriching. We look forward very much to welcoming you to Kiev in May 2018 for the Dopamine- 2018 conference.
NBScience Events Department


Outside the central nervous system, dopamine functions primarily as a local chemical messenger. In blood vessels, it inhibits norepinephrine release and acts as a vasodilator (at normal concentrations); in the kidneys, it increases sodium excretion and urine output; in the pancreas, it reduces insulin production; in the digestive system, it reduces gastrointestinal motility and protects intestinal mucosa; and in the immune system, it reduces the activity of lymphocytes. With the exception of the blood vessels, dopamine in each of these peripheral systems is synthesized locally and exerts its effects near the cells that release it.

Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson’s disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra.


Please click here for registration.

Deadline for registration – December 19, 2017

Conference location : Expo Plaza, Kiev, Ukraine

Salyutna str. 2


Registration Fees
If you wish to take advantage of discounted registration fees, it is strongly recommended to register by December 19, 2017
to meet early advanced registration.
Early Advance Registration
by December 19, 2017
Advance Registration
by February 01, 2018
485 Euros 585 Euros


Conference topics:

Day 1

Disease, disorders, and pharmacology

The dopamine system plays a central role in several significant medical conditions, including Parkinson’s disease, attention deficit hyperactivity disorder, schizophrenia, and addiction. Aside from dopamine itself, there are many other important drugs that act on dopamine systems in various parts of the brain or body.

Aging brain

A number of studies have reported an age-related decline in dopamine synthesis and dopamine receptor density (i.e., the number of receptors) in the brain

This decline has been shown to occur in the striatum and extrastriatal regions.
Other neurotransmitters, such as serotonin and glutamate also show a decline in output with aging.

Parkinson’s disease
Parkinson’s disease is an age-related disorder characterized by movement disorders such as stiffness of the body, slowing of movement, and trembling of limbs when they are not in use.


Drug addiction and psychostimulants

Diagram describes the mechanisms by which cocaine and amphetamines reduce dopamine transporter activity.
Cocaine increases dopamine levels by blocking dopamine transporters (DAT), which transport dopamine back into a synaptic terminal after it has been emitted.
Cocaine, substituted amphetamines (including methamphetamine), Adderall, methylphenidate (marketed as Ritalin or Concerta), MDMA (ecstasy) and other psychostimulants exert their effects primarily or partly by increasing dopamine levels in the brain by a variety of mechanisms.
The dopamine system plays a crucial role in several aspects of addiction. At the earliest stage, genetic differences that alter the expression of dopamine receptors in the brain can predict whether a person will find stimulants appealing or aversive

Consumption of stimulants produces increases in brain dopamine levels that last from minutes to hours

Finally, the chronic elevation in dopamine that comes with repetitive high-dose stimulant consumption triggers a wide-ranging set of structural changes in the brain that are responsible for the behavioral abnormalities which characterize an addiction.

Treatment of stimulant addiction is very difficult, because even if consumption ceases, the craving that comes with psychological withdrawal does not.

Even when the craving seems to be extinct, it may re-emerge when faced with stimuli that are associated with the drug, such as friends, locations and situations.

Psychosis and antipsychotic drugs

Psychiatrists in the early 1950s discovered that a class of drugs known as typical antipsychotics (also known as major tranquilizers), were often effective at reducing the psychotic symptoms of schizophrenia. The introduction of the first widely used antipsychotic, chlorpromazine (Thorazine), in the 1950s, led to the release of many patients with schizophrenia from institutions in the years that followed.
By the 1970s researchers understood that these typical antipsychotics worked as antagonists on the D2 receptors.

This realization led to the so-called dopamine hypothesis of schizophrenia, which postulates that schizophrenia is largely caused by hyperactivity of brain dopamine systems.


Day 2

Attention deficit hyperactivity disorder
Altered dopamine neurotransmission is implicated in attention deficit hyperactivity disorder (ADHD), a condition associated with impaired cognitive control, in turn leading to problems with regulating attention (attentional control), inhibiting behaviors (inhibitory control), and forgetting things or missing details (working memory), among other problems.

Dopamine plays a role in pain processing in multiple levels of the central nervous system including the spinal cord, periaqueductal gray, thalamus, basal ganglia, and cingulate cortex.

Decreased levels of dopamine have been associated with painful symptoms that frequently occur in Parkinson’s disease.

Nausea and vomiting are largely determined by activity in the area postrema in the medulla of the brainstem, in a region known as the chemoreceptor trigger zone.

Dopamine sources
Dopamine consumed in food cannot act on the brain, because it cannot cross the bloodbrain barrier. However, there are also a variety of plants that contain L-DOPA, the metabolic precursor of dopamine.
The highest concentrations are found in the leaves and bean pods of plants of the genus Mucuna, especially in Mucuna pruriens (velvet beans), which have been used as a source for L-DOPA as a drug.

In a species of marine green algae Ulvaria obscura, a major component of some algal blooms, dopamine is present in very high concentrations, estimated at 4.4% of dry weight. There is evidence that this dopamine functions as an anti-herbivore defense, reducing consumption by snails and isopods.

Dopamine pharmacology, medicines, clinical research


contract research organization

stem cell therapy